Private Manufacturers’ Thresholds to Invest in Comparative Effectiveness Trials View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-10

AUTHORS

Anirban Basu, David Meltzer

ABSTRACT

The recent rush of enthusiasm for public investment in comparative effectiveness research (CER) in the US has focussed attention on these public investments. However, little attention has been given to how changing public investment in CER may affect private manufacturers' incentives for CER, which has long been a major source of CER. In this work, based on a simple revenue maximizing economic framework, we generate predictions on thresholds to invest in CER for a private manufacturer that compares its own product to a competitor's product in head-to-head trials. Our analysis shows that private incentives to invest in CER are determined by how the results of CER may affect the price and quantity of the product sold and the duration over which resulting changes in revenue would accrue, given the time required to complete CER and the time from the completion of CER to the time of patent expiration. We highlight the result that private incentives may often be less than public incentives to invest in CER and may even be negative if the likelihood of adverse findings is sufficient. We find that these incentives imply a number of predictions about patterns of CER and how they will be affected by changes in public financing of CER and CER methods. For example, these incentives imply that incumbent patent holders may be less likely to invest in CER than entrants and that public investments in CER may crowd out similar private investments. In contrast, newer designs and methods for CER, such as Bayesian adaptive trials, which can reduce ex post risk of unfavourable results and shorten the time for the production of CER, may increase the expected benefits of CER and may tend to increase private investment in CER as long as the costs of such innovative designs are not excessive. Bayesian approaches to design also naturally highlight the dynamic aspects of CER, allowing less expensive initial studies to guide decisions about future investments and thereby encouraging greater initial investments in CER. However, whether the potential effects we highlight of public funding of CER and of Bayesian approaches to trial design actually produce changes in private investment in CER remains an empirical question. More... »

PAGES

859-868

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/11597730-000000000-00000

DOI

http://dx.doi.org/10.2165/11597730-000000000-00000

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1019885179

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22901018


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Comparative Effectiveness Research", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Controlled Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Industry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Investments", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Support as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National Bureau of Economic Research", 
          "id": "https://www.grid.ac/institutes/grid.250279.b", 
          "name": [
            "Department of Health Services and Pharmaceutical Outcomes Research and Policy Program (PORPP), University of Washington, Box 357660, WA 98195-7660, Seattle, 1959 NE Pacific StWashington, USA", 
            "The National Bureau of Economic Research, Cambridge, Massachusetts, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Basu", 
        "givenName": "Anirban", 
        "id": "sg:person.0730057660.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730057660.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Medicine, Department of Economics, and the Graduate School of Public Policy Studies, University of Chicago, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meltzer", 
        "givenName": "David", 
        "id": "sg:person.01246417251.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246417251.29"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.jhealeco.2011.05.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015348938"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd1927", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018773545", 
          "https://doi.org/10.1038/nrd1927"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd1927", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018773545", 
          "https://doi.org/10.1038/nrd1927"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11539400-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027257327", 
          "https://doi.org/10.2165/11539400-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11539400-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027257327", 
          "https://doi.org/10.2165/11539400-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1377/hlthaff.24.1.93", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031536728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/criticalvalues/3.1.16", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032512764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0167-6296(00)00071-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037426466"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0272989x11412975", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038011973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0272989x11412975", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038011973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0167-6296(98)00039-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047702943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0272989x04263162", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052641022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0272989x04263162", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052641022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.290.12.1624", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053305111"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1162/0033553041502144", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063348973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-151-3-200908040-00126", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073710949"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078846482", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-10", 
    "datePublishedReg": "2012-10-01", 
    "description": "The recent rush of enthusiasm for public investment in comparative effectiveness research (CER) in the US has focussed attention on these public investments. However, little attention has been given to how changing public investment in CER may affect private manufacturers' incentives for CER, which has long been a major source of CER. In this work, based on a simple revenue maximizing economic framework, we generate predictions on thresholds to invest in CER for a private manufacturer that compares its own product to a competitor's product in head-to-head trials. Our analysis shows that private incentives to invest in CER are determined by how the results of CER may affect the price and quantity of the product sold and the duration over which resulting changes in revenue would accrue, given the time required to complete CER and the time from the completion of CER to the time of patent expiration. We highlight the result that private incentives may often be less than public incentives to invest in CER and may even be negative if the likelihood of adverse findings is sufficient. We find that these incentives imply a number of predictions about patterns of CER and how they will be affected by changes in public financing of CER and CER methods. For example, these incentives imply that incumbent patent holders may be less likely to invest in CER than entrants and that public investments in CER may crowd out similar private investments. In contrast, newer designs and methods for CER, such as Bayesian adaptive trials, which can reduce ex post risk of unfavourable results and shorten the time for the production of CER, may increase the expected benefits of CER and may tend to increase private investment in CER as long as the costs of such innovative designs are not excessive. Bayesian approaches to design also naturally highlight the dynamic aspects of CER, allowing less expensive initial studies to guide decisions about future investments and thereby encouraging greater initial investments in CER. However, whether the potential effects we highlight of public funding of CER and of Bayesian approaches to trial design actually produce changes in private investment in CER remains an empirical question.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/11597730-000000000-00000", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2551756", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2669598", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "30"
      }
    ], 
    "name": "Private Manufacturers\u2019 Thresholds to Invest in Comparative Effectiveness Trials", 
    "pagination": "859-868", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5ebe3e253a40898369cf184e5810dd274df0c4cb62d40d5d3232ac8feb610582"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22901018"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9212404"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/11597730-000000000-00000"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1019885179"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/11597730-000000000-00000", 
      "https://app.dimensions.ai/details/publication/pub.1019885179"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000504.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165%2F11597730-000000000-00000"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/11597730-000000000-00000'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/11597730-000000000-00000'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/11597730-000000000-00000'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/11597730-000000000-00000'


 

This table displays all metadata directly associated to this object as RDF triples.

155 TRIPLES      21 PREDICATES      50 URIs      29 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/11597730-000000000-00000 schema:about N1391ebd4d63b42bd92e2e1b5ceae4edb
2 N1d637789c01c4d999ae216d38b41a03b
3 N1ecbe11229f841938fdd438c4fec4850
4 N60b7296459f745778fe3c70cc660882a
5 N61ffcdf5c4004758a5120bbe779f0ac9
6 N6b4f74f712514e6388e3014a989627d7
7 Nb6806d1bb3b84dabb421d5b7bce6f71c
8 Ncfa78cf66c26498bb0ca2704d028d1ec
9 anzsrc-for:14
10 anzsrc-for:1402
11 schema:author Naa68fa8c510d4606a46641ead0922eb4
12 schema:citation sg:pub.10.1038/nrd1927
13 sg:pub.10.2165/11539400-000000000-00000
14 https://app.dimensions.ai/details/publication/pub.1078846482
15 https://doi.org/10.1001/jama.290.12.1624
16 https://doi.org/10.1016/j.jhealeco.2011.05.012
17 https://doi.org/10.1016/s0167-6296(00)00071-0
18 https://doi.org/10.1016/s0167-6296(98)00039-3
19 https://doi.org/10.1093/criticalvalues/3.1.16
20 https://doi.org/10.1162/0033553041502144
21 https://doi.org/10.1177/0272989x04263162
22 https://doi.org/10.1177/0272989x11412975
23 https://doi.org/10.1377/hlthaff.24.1.93
24 https://doi.org/10.7326/0003-4819-151-3-200908040-00126
25 schema:datePublished 2012-10
26 schema:datePublishedReg 2012-10-01
27 schema:description The recent rush of enthusiasm for public investment in comparative effectiveness research (CER) in the US has focussed attention on these public investments. However, little attention has been given to how changing public investment in CER may affect private manufacturers' incentives for CER, which has long been a major source of CER. In this work, based on a simple revenue maximizing economic framework, we generate predictions on thresholds to invest in CER for a private manufacturer that compares its own product to a competitor's product in head-to-head trials. Our analysis shows that private incentives to invest in CER are determined by how the results of CER may affect the price and quantity of the product sold and the duration over which resulting changes in revenue would accrue, given the time required to complete CER and the time from the completion of CER to the time of patent expiration. We highlight the result that private incentives may often be less than public incentives to invest in CER and may even be negative if the likelihood of adverse findings is sufficient. We find that these incentives imply a number of predictions about patterns of CER and how they will be affected by changes in public financing of CER and CER methods. For example, these incentives imply that incumbent patent holders may be less likely to invest in CER than entrants and that public investments in CER may crowd out similar private investments. In contrast, newer designs and methods for CER, such as Bayesian adaptive trials, which can reduce ex post risk of unfavourable results and shorten the time for the production of CER, may increase the expected benefits of CER and may tend to increase private investment in CER as long as the costs of such innovative designs are not excessive. Bayesian approaches to design also naturally highlight the dynamic aspects of CER, allowing less expensive initial studies to guide decisions about future investments and thereby encouraging greater initial investments in CER. However, whether the potential effects we highlight of public funding of CER and of Bayesian approaches to trial design actually produce changes in private investment in CER remains an empirical question.
28 schema:genre research_article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N6a481269ef8f48b7b9f9680c2e459c2e
32 N7eeb40b48270419fa1a8bf2afa598294
33 sg:journal.1102812
34 schema:name Private Manufacturers’ Thresholds to Invest in Comparative Effectiveness Trials
35 schema:pagination 859-868
36 schema:productId N0871dbe2a6754dea94a5f3f69902382d
37 N2421e58d99a64d5a933a87befa8fbf07
38 N369b906cc27e452ab87aa08ef2185b9e
39 N5672c7b1698c4dcfb9552a2e831dd69b
40 N7f2382406a35436ca3b9e6b6acd83f90
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019885179
42 https://doi.org/10.2165/11597730-000000000-00000
43 schema:sdDatePublished 2019-04-10T13:14
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher Ne2a7d7f9bb5a4c01b1a7f8a554877b55
46 schema:url http://link.springer.com/10.2165%2F11597730-000000000-00000
47 sgo:license sg:explorer/license/
48 sgo:sdDataset articles
49 rdf:type schema:ScholarlyArticle
50 N0871dbe2a6754dea94a5f3f69902382d schema:name doi
51 schema:value 10.2165/11597730-000000000-00000
52 rdf:type schema:PropertyValue
53 N1391ebd4d63b42bd92e2e1b5ceae4edb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
54 schema:name Research Support as Topic
55 rdf:type schema:DefinedTerm
56 N1d637789c01c4d999ae216d38b41a03b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Humans
58 rdf:type schema:DefinedTerm
59 N1ecbe11229f841938fdd438c4fec4850 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Research Design
61 rdf:type schema:DefinedTerm
62 N2421e58d99a64d5a933a87befa8fbf07 schema:name nlm_unique_id
63 schema:value 9212404
64 rdf:type schema:PropertyValue
65 N369b906cc27e452ab87aa08ef2185b9e schema:name pubmed_id
66 schema:value 22901018
67 rdf:type schema:PropertyValue
68 N41028ef10cfc4f3f94fbbbf3513da02e schema:name Department of Medicine, Department of Economics, and the Graduate School of Public Policy Studies, University of Chicago, Chicago, Illinois, USA
69 rdf:type schema:Organization
70 N5672c7b1698c4dcfb9552a2e831dd69b schema:name readcube_id
71 schema:value 5ebe3e253a40898369cf184e5810dd274df0c4cb62d40d5d3232ac8feb610582
72 rdf:type schema:PropertyValue
73 N60b7296459f745778fe3c70cc660882a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Controlled Clinical Trials as Topic
75 rdf:type schema:DefinedTerm
76 N61ffcdf5c4004758a5120bbe779f0ac9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Investments
78 rdf:type schema:DefinedTerm
79 N6a481269ef8f48b7b9f9680c2e459c2e schema:volumeNumber 30
80 rdf:type schema:PublicationVolume
81 N6b4f74f712514e6388e3014a989627d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Drug Industry
83 rdf:type schema:DefinedTerm
84 N6cccb9b5c2784e6abe4e13ee8845e9fb rdf:first sg:person.01246417251.29
85 rdf:rest rdf:nil
86 N7eeb40b48270419fa1a8bf2afa598294 schema:issueNumber 10
87 rdf:type schema:PublicationIssue
88 N7f2382406a35436ca3b9e6b6acd83f90 schema:name dimensions_id
89 schema:value pub.1019885179
90 rdf:type schema:PropertyValue
91 Naa68fa8c510d4606a46641ead0922eb4 rdf:first sg:person.0730057660.12
92 rdf:rest N6cccb9b5c2784e6abe4e13ee8845e9fb
93 Nb6806d1bb3b84dabb421d5b7bce6f71c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Comparative Effectiveness Research
95 rdf:type schema:DefinedTerm
96 Ncfa78cf66c26498bb0ca2704d028d1ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name United States
98 rdf:type schema:DefinedTerm
99 Ne2a7d7f9bb5a4c01b1a7f8a554877b55 schema:name Springer Nature - SN SciGraph project
100 rdf:type schema:Organization
101 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
102 schema:name Economics
103 rdf:type schema:DefinedTerm
104 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
105 schema:name Applied Economics
106 rdf:type schema:DefinedTerm
107 sg:grant.2551756 http://pending.schema.org/fundedItem sg:pub.10.2165/11597730-000000000-00000
108 rdf:type schema:MonetaryGrant
109 sg:grant.2669598 http://pending.schema.org/fundedItem sg:pub.10.2165/11597730-000000000-00000
110 rdf:type schema:MonetaryGrant
111 sg:journal.1102812 schema:issn 1170-7690
112 1179-2027
113 schema:name PharmacoEconomics
114 rdf:type schema:Periodical
115 sg:person.01246417251.29 schema:affiliation N41028ef10cfc4f3f94fbbbf3513da02e
116 schema:familyName Meltzer
117 schema:givenName David
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246417251.29
119 rdf:type schema:Person
120 sg:person.0730057660.12 schema:affiliation https://www.grid.ac/institutes/grid.250279.b
121 schema:familyName Basu
122 schema:givenName Anirban
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730057660.12
124 rdf:type schema:Person
125 sg:pub.10.1038/nrd1927 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018773545
126 https://doi.org/10.1038/nrd1927
127 rdf:type schema:CreativeWork
128 sg:pub.10.2165/11539400-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027257327
129 https://doi.org/10.2165/11539400-000000000-00000
130 rdf:type schema:CreativeWork
131 https://app.dimensions.ai/details/publication/pub.1078846482 schema:CreativeWork
132 https://doi.org/10.1001/jama.290.12.1624 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053305111
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1016/j.jhealeco.2011.05.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015348938
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1016/s0167-6296(00)00071-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037426466
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1016/s0167-6296(98)00039-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047702943
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1093/criticalvalues/3.1.16 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032512764
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1162/0033553041502144 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063348973
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1177/0272989x04263162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052641022
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1177/0272989x11412975 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038011973
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1377/hlthaff.24.1.93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031536728
149 rdf:type schema:CreativeWork
150 https://doi.org/10.7326/0003-4819-151-3-200908040-00126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073710949
151 rdf:type schema:CreativeWork
152 https://www.grid.ac/institutes/grid.250279.b schema:alternateName National Bureau of Economic Research
153 schema:name Department of Health Services and Pharmaceutical Outcomes Research and Policy Program (PORPP), University of Washington, Box 357660, WA 98195-7660, Seattle, 1959 NE Pacific StWashington, USA
154 The National Bureau of Economic Research, Cambridge, Massachusetts, USA
155 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...